Home granita machines can help patients with conditions like epilepsy.
But now, researchers are making them more controllable.
Home Granita Machines (HGMs) are the first step in a clinical trial to test a novel home-manufacturing technique called biofeedback.
The HGMs are used to treat epilepsy patients who have difficulty controlling their seizures and are unable to use conventional therapies.
They have already been shown to reduce seizures in children with epilepsy.
In a new study, researchers from Duke University in Durham, North Carolina, tested HGMs to treat patients with epilepsy who have trouble controlling their seizure frequency and require a medication.
“The patients we’ve tested have a very low seizure frequency,” said Dr. Toni Leichtman, lead author of the study and a clinical associate professor of neurology at Duke University.
“When we put them in a room with these HGMs, the seizure frequency actually decreases, because we control the amount of electrical activity.
We’re basically giving the patient a medication that they’ve been unable to control.”
The study is published in the journal PLOS One.HGMS devices have been developed for the treatment of epilepsy in the past.
But until now, the devices were not widely available, and many patients did not have access to them.
Researchers hope the new HGMs will help to address these issues.
“There’s no question that we can’t do all the things that these devices are supposed to do, which is control seizures,” Leichtmans co-author said.
“We want to get to a point where we can control these things with these devices.”
The devices have the potential to be used in the field for other conditions, such as neurodegenerative disorders.
In the future, the researchers hope to expand the trial to other types of epilepsy, such Alzheimer’s disease.HMG devices can be controlled by a computer or smartphone app, but the study focused on the treatment.
“We wanted to see if the HGMs were also effective at controlling seizures and how much they can help a patient control seizures without medication,” said Leichtmann.
“What we found is that they can be effective at these conditions.”
The researchers tested a number of different HGMs in a controlled setting, including the one that they designed to treat the patient with epilepsy, as well as two others.
The devices can help to reduce the frequency of seizures in the brain.
“You can put the device in a bedroom, a conference room, a meeting room, or anywhere where you want to control the frequency,” Leichmann said.
The researchers also tested a device that they called an electrotherapeutic device, which helps to control seizures by stimulating the central nervous system with electrical currents.
The study found that HGMs worked better in patients with a lower seizure frequency than those with a higher seizure frequency.
“These results demonstrate that the HGMS is more effective in patients at low seizure frequencies than in patients who are very high,” Leishman said.
“They can also be used to control epileptic seizures that are very severe.”
The team is working on making the devices more controlly adjustable.
“I think there’s a lot of room for improvement,” Leischman said, “but we’re optimistic that HGMS devices can become a viable tool for the future treatment of epileptic disorders.”